Key Laboratory of Emergency and Trauma of Ministry of Education, Engineering Research Center for Hainan Biological Sample Resources of Major Diseases, The Hainan Branch of National Clinical Research Center for Cancer, the First Clinical College & the First Affiliated Hospital, Hainan Medical University, Haikou, 570102, China.
Key Laboratory of Tropical Cardiovascular Diseases Research of Hainan Province, Hainan Women and Children's Medical Center, Hainan Medical University, Haikou, 571199, China.
J Nanobiotechnology. 2024 Sep 30;22(1):592. doi: 10.1186/s12951-024-02836-3.
Immunotherapy has shown marked progress in promoting systemic anti-colorectal cancer (CRC) clinical effects. For further effectively sensitizing CRC to immunotherapy, we have engineered a pH-sensitive zeolitic imidazolate framework-8 (CS/NPs), capable of efficient cGAS-STING pathway activation and immune checkpoint blockade, by encapsulating the chemotherapeutic mitoxantrone (MTX) and immunomodulator thymus pentapeptide (TP5) and tailoring with tumor-targeting chondroitin sulfate (CS). In this nanoframework, CS endows CS/NPs with specific tumor-targeting activity and reduced systemic toxicity. Of note, the coordinated Zn disrupts glycolytic processes and downregulates the expression of glucose transporter type 1 (GLUT1), thus depriving the cancer cells of their energy. Zn further initiates the adenosine 5'-monophosphate activated protein kinase (AMPK) pathway, which leads to PD-L1 protein degradation and sensitizes CRC cells to immunotherapy. Moreover, the damaged double-stranded DNA during MTX treatment activates the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, which works together with TP5 induced the proliferation and differentiation of T lymphocytes and dendritic cells to further enhance the anti-CRC immune response. Therefore, CS/NPs efficiently sensitize cells to chemotherapy and stimulate systemic antitumor immune responses both in vitro and in vivo, representing a promising strategy to increase the feasibility of CRC immunotherapy.
免疫疗法在促进全身性抗结直肠癌(CRC)的临床效果方面取得了显著进展。为了进一步有效地使 CRC 对免疫疗法敏感,我们通过封装化疗药物米托蒽醌(MTX)和免疫调节剂胸腺五肽(TP5),并与肿瘤靶向硫酸软骨素(CS)进行修饰,设计了一种 pH 敏感的沸石咪唑酯骨架-8(CS/NPs)。在这种纳米框架中,CS 赋予 CS/NPs 特异性的肿瘤靶向活性和降低的全身毒性。值得注意的是,协调的 Zn 破坏糖酵解过程并下调葡萄糖转运蛋白 1(GLUT1)的表达,从而剥夺癌细胞的能量。Zn 进一步引发 5'-单磷酸腺苷激活蛋白激酶(AMPK)通路,导致 PD-L1 蛋白降解,并使 CRC 细胞对免疫疗法敏感。此外,MTX 治疗过程中受损的双链 DNA 激活环鸟苷酸-AMP 合酶-干扰素基因刺激物(cGAS-STING)通路,与 TP5 一起诱导 T 淋巴细胞和树突状细胞的增殖和分化,从而进一步增强抗 CRC 免疫反应。因此,CS/NPs 可有效地使细胞对化疗敏感,并在体外和体内刺激全身性抗肿瘤免疫反应,代表了提高 CRC 免疫疗法可行性的有前途的策略。